A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
A phase 3 trial testing TQB2102 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, now recruiting.
Overview
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer is a phase 3 interventional study registered as NCT07043725, led by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression. Planned enrolment is 544 participants (estimated). The study started in 2025-09-15 and primary completion is expected in 2027-09. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialTo Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialClinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.